^
Association details:
| Biomarker: | EGFR G719S + EGFR S768I |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to: Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations
Published date:
05/11/2021
Excerpt:
We report the case of an 81‐year‐old patient who was referred to our center after a diagnosis of lung adenocarcinoma...EGFR mutational analysis revealed concomitant G719S exon 18 and S768I exon 20 mutations….In the same month, the recurrence of severe skin toxicity necessitated a further afatinib dose reduction to 20 mg per day....our patient did not progress precociously after commencing afatinib.
DOI:
https://doi.org/10.1111/1759-7714.13997
